Peregrine Pharmaceuticals (PPHM) Posts Narrower than Expected Loss of 10c/Share

Peregrine Pharmaceuticals (NASDAQ: PPHM) reported Q4 EPS of ($0.10), $0.03 better than the analyst estimate of ($0.13). Revenue for the quarter came in at $2.07 million versus the consensus estimate of $2.64 million.

For earnings history and earnings-related data on Peregrine Pharmaceuticals (PPHM) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• S&P 500 may pull back before midterms, but Citi says buy the dip
• Morgan Stanley course-corrects their semiconductor equipment outlook on demand